Summary
Amundi MSCI EMU Value Factor UCITS ETF Dist (VAL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amundi MSCI EMU Value Factor UCITS ETF Dist ever had a stock split?
Amundi MSCI EMU Value Factor UCITS ETF Dist Profile
| Biotechnology Industry | Healthcare Sector | Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. CEO | LSE Exchange | LU1598690169 ISIN |
| United Kingdom Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ValiRx plc is a biopharmaceutical company based in England, United Kingdom, focused on the development of therapeutic products and companion diagnostics for cancer treatment. Founded in 2000, the company has been dedicated to creating innovative solutions for oncology, specifically targeting prostate cancer, non-small cell lung cancer, and endometriosis, along with developing treatments for severe symptoms of Covid-19. With a commitment to advancing healthcare through research, ValiRx combines scientific expertise with a passion for improving patient outcomes.
Products and Services
- VAL201
- VAL401
- VAL301
- BC201
- CLX001
A short peptide that targets prostate cancer, VAL201 has successfully completed Phase I/II clinical trials. It represents the company's dedication to combatting one of the most common types of cancer affecting men, showcasing ValiRx's forward-thinking approach to oncology.
A reformulated version of the anti-psychotic drug risperidone, VAL401 has completed a Phase II clinical trial for treating end-stage non-small cell lung cancer. This innovative application reflects the company’s strategy of repurposing existing drugs to provide new cancer therapies.
In pre-clinical development, VAL301 is a peptide ingredient aimed at treating endometriosis. This effort to tackle a painful and often debilitating condition that affects millions of women worldwide underscores ValiRx’s commitment to addressing a broad spectrum of unmet medical needs.
This combination of the peptide ingredient of VAL201/VAL301 with complementary active components is being developed for the treatment of patients suffering from severe symptoms of Covid-19. BC201 exemplifies the company’s agility in responding to global health crises by leveraging its existing technology portfolio.
A peptide nanoparticle formulation in pre-clinical trial stages, CLX001 is designed for the destruction of cancer cells. This innovative approach to oncology treatment signals ValiRx's continual pursuit of novel and effective solutions in the fight against cancer.
Contact Information
